Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).
As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.
Panel Discussion: The Next Normal: Predictions for the Future of Advanced Medicines
Precision attended this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. On April 20th our team of experts lead meaningful discussions throughout, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies. This panel discussion focused on the sector’s continued success and challenges that lie ahead in research and development, manufacturing, regulatory, pricing, and reimbursement. Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies.
Moderated by Anshul Mangal (President of Project Farma / Precision ADVANCE) this discussion will feature insights from Robert Ang (President & CEO Vor Biopharma), Deb Phippard (CSO Precision for Medicine / Precision ADVANCE), Brent Rice (SVP & CCO Autolus Therapeutics) and Johanna Rossell (CCO Enzyvant Therapeutics).
Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
Click here to learn more about the model and the team’s findings.
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.
This white paper is based on a panel discussion sponsored by Precision ADVANCE at the 2021 Meeting on the Mesa conference and features insights from C-suite leaders on the current CGTx investment landscape, technology innovations, talent shortage and the evolution of reimbursement payment models.
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- R.A. Session II: President, Founder and CEO (Taysha Gene Therapies)
- Palani Palaniappan: EVP and CTO (Aruvant Sciences)
- Derrell Porter: Founder and CEO (Cellevolve Bio)
- Claudia Zylberberg: Founder and Executive Chair (Akron Bio)
- Phil Cyr: SVP (Precision Value & Health)